Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nanoform Finland Oyj : Share subscriptions based on Nanoform Finland Plc's multiple Stock Option Programs

06/11/2021 | 11:23am EDT

Company release

Nanoform Finland Plc

June 11, 2021

06:15 p.m. Finnish time / 05:15 p.m. Swedish time

Share subscriptions based on Nanoform Finland Plc's multiple Stock Option Programs

Helsinki, Finland- Between June 4 and June 7, 2021, a total of 168,700 Nanoform Finland Plc's (the 'Company' or 'Nanoform') new shares have been subscribed for with the Company's 2/2019, 3/2019, 5/2019 and 1/2020 stock options programs. The entire subscription price for subscriptions made with the stock options of EUR 187,505 will be entered in the Company's reserve for invested unrestricted equity.

The shares subscribed for under the stock options are expected to be registered in the Trade Register on or about June 18, 2021 as of which date the new shares will establish shareholder rights. As a result of registering the new shares, the number of Nanoform shares is 72,535,146 in total. The new shares will be admitted to trading on Nasdaq First North Premier Growth Market Finland and Sweden on or about June 23, 2021.

For further information, please contact:

Peter Hänninen

General Counsel

peter.hanninen@nanoform.com / +358 50 353 040

For investor relations queries, please contact:

Henri von Haartman

Director of Investor Relations

hvh@nanoform.com/ +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information, please visit www.nanoform.com.

Disclaimer

Nanoform Finland Oyj published this content on 11 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 June 2021 15:22:01 UTC.


ę Publicnow 2021
All news about NANOFORM FINLAND OYJ
07:31aNANOFORM FINLAND OYJ : shortlisted for the European Small and Mid-Cap Awards 2021
AQ
09/09NANOFORM FINLAND OYJ : Herantis Pharma Complete Parkinson's Drug Combo Proof Of Concept
MT
09/09NANOFORM FINLAND OYJ : technology delivers successful results for Herantis CDNF drug candi..
AQ
09/09HERANTIS PHARMA OYJ : Announces Successful rhCDNF Results With Nanoform Technology
AQ
09/09Nanoform technology delivers successful results for Herantis CDNF drug candidate
CI
08/27NANOFORM FINLAND OYJ : The Board of Directors of Nanoform Finland Plc decided on issue of ..
AQ
08/26NANOFORM FINLAND OYJ : Interim Report for January-June 2021 – Report
PU
08/26NANOFORM FINLAND OYJ : Interim Report January – June 2021
PU
08/26NANOFORM FINLAND OYJ : Interim Report January - June 2021
AQ
08/26Nanoform Finland Oyj Announces Consolidated Earnings Results for the Second Quarter and..
CI
More news
Financials
Sales 2021 2,85 M 3,35 M 3,35 M
Net income 2021 -19,3 M -22,7 M -22,7 M
Net cash 2021 72,2 M 84,8 M 84,8 M
P/E ratio 2021 -28,6x
Yield 2021 -
Capitalization 577 M 678 M 678 M
EV / Sales 2021 177x
EV / Sales 2022 57,7x
Nbr of Employees 106
Free-Float 68,0%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 7,72 €
Average target price 9,15 €
Spread / Average Target 18,5%
EPS Revisions
Managers and Directors
Edward HŠggstr÷m Chief Executive Officer
Albert Hńggstr÷m Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Gonšalo Nuno N. da Silva Rebelo de Andrade Chief Business Operations
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ9.04%657
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY38.48%206 972